Economy

GreenLight Biosciences or the RNA at every level

After genetic sequences and DNA, here comes RNA, the new flagship molecule in biotechnology that is supposed to solve agricultural and health problems. Companies in this field are flourishing. Among them is GreenLight Biosciences, a company that was on the verge of bankruptcy when it was bought by the investment fund Fall Line Capital.

EU: vitamins and additives produced by GMOs

European organic food processors say « no » to GMOs/NGTs

European organic food processors say “no” to GMOs/NGTs

GMO-derived enzymes used in food and feed

GMO-derived enzymes used in food and feed

Journal

Patents on living organisms: a growing appropriation

Journal

Patents on NGTs, between disputes and desire: the case of Crispr-Cas 9

Journal

Seed patents: the industry’s great manoeuvres

Patents on genetic sequences: excess and fragility

Some seed companies are opposing patents but…

EPO : new GMOs can be differentiated

According to companies, GMO products of genetic modification techniques are patentable because they are considered “inventions”. But to obtain these patents, the European Patent Office (EPO) require from the applicants to be clear about the techniques used for obtaining the organisms or genetic sequences covered by their patent. This obligation shows that, for the EPO, it is possible to differentiate, e.g. between GMOs obtained by patentable mutagenesis techniques on the one hand, and GMOs obtained by other techniques or any other organisms present in nature, on the other hand.